Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene

British Journal of Cancer

Volumn 86, Issue 7, 2002, Pages 1028-1033

  Maring, J G ^a   Van Kuilenburg, A B P ^b   Haasjes, J ^b   Piersma, H ^c   Groen, H J M ^d   Uges, D R A ^d   Van Gennip, A H ^b   De Vries, E G E ^d  

^a Bethesda Hospital   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c MARTINI HOSPITAL   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

5 fluorouracil; DPD; DPYD gene; Mutation; Pharmacogenetics; Pharmacokinetics

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; FOLINIC ACID; GENE PRODUCT;

ADULT; AGED; ALLELE; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DISEASE SEVERITY; DNA SEQUENCE; DRUG CLEARANCE; ENZYME ACTIVITY; ENZYME INACTIVATION; FEMALE; GENE MUTATION; HETEROZYGOSITY; HUMAN; MALE; MONONUCLEAR CELL; POINT MUTATION; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

AGED; ALLELES; ANTIMETABOLITES, ANTINEOPLASTIC; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLORECTAL NEOPLASMS; DIHYDROURACIL DEHYDROGENASE (NADP); DNA, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; OXIDOREDUCTASES; POINT MUTATION; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA;

EID: 0037041639     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600208     Document Type: Article

References (25)

1. Simultaneous determination of dihydrofluorouracil and 5-fluorouracil in plasma by high-performance liquid chromatography
2. Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver
3. Known variant DPYD alleles do not explain DPD deficiency in cancer patients
4. Familial deficiency of dihydropyrimine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil induced toxicity
5. Population study of dihydropyrimidine dehydrogenase in cancer patients
6. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients
7. No effect of dose, hepatic function, or nutrional status on 5-FU clearance following continuous (5-day) 5-FU infusion
8. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion
9. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine and bile
10. Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as substrate
11. Structural organization of the human dihydropyrimidine dehydrogenase gene
12. Dihydropyrimine dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified patients, and clinical implication in 5-fluorouracil chemotherapy
13. Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy
14. Decreased dihydropyrimine dehydrogenase activity in a population of patients with breast cancer: Implication for 5-fluorouracil-based chemotherapy
15. Autoregulation of 5-fluorouracil metabolism
16. Fluorouracil: Biochemistry and pharmacology
17. Pharmacokinetics of 5-fluorouracil after short systemic infusion: Plasma level at the end of the distribution phase as an indicator of the total area under the plasma concentration - Time curve
18. Measurement of protein using bicinchoninic acid
19. Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil related toxicities
20. Dose and time dependencies of 5-fluorouracil pharmacokinetics
21. Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimine dehydrogenase and severe 5-fluorouracil related toxicity
22. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil associated toxicity. Identification of new mutations in the DPD gene
23. Pitfalls in the diagnosis of patients with partial dihydropyrimidine dehydrogenase deficiency
24. Lethal outcome of a patient with complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: Frequency of the common IVS14+1G>A mutation causing DPD deficiency
25. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity